APL

VERSES and NASA Partner to Pursue Standards for Space Industry

Retrieved on: 
Thursday, November 30, 2023
Government, JPL, Policy, DARPA, NEO, European Commission, PWC, Electricity, Natural Resources, APL, Genius, Mining, City, Open Geospatial Consortium, Artemis Accords, Architecture, NASA, SDO, Electronics, Jet Propulsion Laboratory, IEEE, Safety, Scattered disc, Artemis, Morgan Stanley, Asset management

NASA seeks to advance international and interagency collaboration on space exploration efforts through technology and policy standards.

Key Points: 
  • NASA seeks to advance international and interagency collaboration on space exploration efforts through technology and policy standards.
  • NASA, JPL and many other stakeholders in the new “space race” have a vested interest in standardizing infrastructure and supporting the space economy, which Morgan Stanley estimates may grow to $1 Trillion by 2040.
  • The international space agency community is actively seeking to develop standards for space exploration.
  • Therefore, the Artemis Accords call for partner nations to utilize open international standards, develop new standards when necessary, and strive to support interoperability to the greatest extent practical,” says NASA.

ZCG-Backed Unimed Appoints Søren Andersen as CEO

Retrieved on: 
Wednesday, December 20, 2023
Medical Supplies, Health, Consulting, Banking, Professional Services, Maritime, Logistics, Supply Chain Management, Transport, StormGeo, London Business School, Multimedia, APL, Business administration, M.B.A, Danish art, Rickmers, Columbia Business School, Weather, Growth, Intelligence, Aarhus University, Economics, Data science, Management

Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry, today announced that international maritime executive Søren Andersen has joined the Company as Chief Executive Officer.

Key Points: 
  • Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry, today announced that international maritime executive Søren Andersen has joined the Company as Chief Executive Officer.
  • Mr. Andersen succeeds Alan Kessman, who will transition to a senior advisor role within the Company.
  • View the full release here: https://www.businesswire.com/news/home/20231220959641/en/
    Mr. Andersen brings a strong track record of leading international and private equity-backed companies in both commercial and operational roles within the maritime industry.
  • As CEO, Mr. Andersen will be responsible for the long-term strategic direction of the Company and the execution of its growth- and profitability-oriented objectives.

University of Phoenix Named a Finalist for 2023 Gartner® Eye on Innovation Award for Education

Retrieved on: 
Monday, December 18, 2023
Human Resources, Continuing, Professional Services, Technology, University, Education, Other Technology, Business, Faculty, Culture, AWS, APL, Student, University of Phoenix, Environment, College, Information technology, CIO, Machine learning, The Economist, Growth, Pediatric intensive care unit, Nursing

University of Phoenix proudly announces its recognition as a finalist for the 2023 Gartner® Eye on Innovation Award for Education in the category of "Enhancing IT People, Processes and Skills" category.

Key Points: 
  • University of Phoenix proudly announces its recognition as a finalist for the 2023 Gartner® Eye on Innovation Award for Education in the category of "Enhancing IT People, Processes and Skills" category.
  • The move to a “manager-free approach” for IT engineers reflects the University's commitment to fostering innovation in the realm of Information Technology and education.
  • The team of University of Phoenix APLs included in this recognition are:
    Senior APLs included in this recognition are Dr. Tiefa “Ty” Jones and Kris Neville.
  • University of Phoenix Senior APL, Dr. Ty Jones, expressed her enthusiasm for the recognition, stating, "We believe that being named a finalist for the Gartner Eye on Innovation Award is a testament to the dedication and ingenuity of our leadership, faculty, and staff.

Andrew Peller Limited Reports Solid Results and Improved Profitability in Second Quarter of Fiscal 2024 and Announces Leadership Continuity Plans

Retrieved on: 
Friday, November 10, 2023
WSSP, EBITA, CFO, Wine, Consultant, Public expenditure, APL, Marketing, Independent Payment Advisory Board, Agriculture and Agri-Food Canada, Security (finance), Cryptocurrency, Management

Gross margin as a percentage of sales improved to 40.0% for the six months ended September 30, 2023, from 38.9% in the prior year.

Key Points: 
  • Gross margin as a percentage of sales improved to 40.0% for the six months ended September 30, 2023, from 38.9% in the prior year.
  • In the second quarter of fiscal 2024, gross margin improved to 41.2%, from 38.8% in the same prior year quarter, including a $4.1 million reduction related to the WSSP.
  • For the second quarter of fiscal 2024 selling and administrative expenses were 26.1% of sales, improved from 27.3% in the same prior year period.
  • EBITA in the second quarter of fiscal 2024 was $15.1 million, up from $11.7 million in the second quarter of fiscal 2023.

Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML

Retrieved on: 
Thursday, November 9, 2023
EHA, CD38, Associate, UCSF Benioff Children's Hospital, European Hematology Association, Juvenile myelomonocytic leukemia, Transplant, Disease, Database, UCSF, Patient, ASCO, Hematopoietic stem cell transplantation, APL, AZA, Blood, Cytarabine, FLA, Cancer, Tretinoin, Acute promyelocytic leukemia, Trial of the century, Malignancy, Society, Physician, Cell, Bone marrow, Drug combination, Pharmaceutical industry, JMML

FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced the publication of data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more effective pre-hematopoietic stem cell transplantation (pre-HSCT) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) in the November 9th Issue of the American Society of Clinical Oncology (ASCO) Journal JCO Precision Oncology. Part of this data was recently presented at the European Hematology Association (EHA) Hybrid Congress held in Frankfurt, Germany on June 8 – 15, 2023. Details of that presentation can be found on the Company’s website at https://notablelabs.com/.

Key Points: 
  • JMML is a rare, aggressive pediatric malignancy for which curative treatment is restricted to hematopoietic stem cell transplantation.
  • Pre-HSCT therapies, i.e., therapies prior to transplantation, include moderately intensive chemotherapy (particularly fludarabine and cytarabine in combination (FLA)) and azacytidine (AZA) monotherapy.
  • Applying its proprietary PPMP technology to blood or bone marrow samples from JMML patients, Notable screened 130 drug combinations and discovered that 27 of these combinations (26 dual-, 1 triple-combination) were more effective ex vivo than the components of these combinations tested individually.
  • “This publication marks the culmination of a multi-year collaboration between UCSF and Notable Labs,” remarked Dr. Stieglitz.

KBRA Assigns Preliminary Ratings to APL Finance 2023-1 Designated Activity Company

Retrieved on: 
Friday, December 8, 2023
Professional Services, Finance, Aircraft, Note, KBRA, Facility, Asset, Davidson Kempner Capital Management, ABS, APL, Telescopic sight

KBRA assigns preliminary ratings to four series of notes issued by APL Finance 2023-1 Designated Activity Company and APL Finance 2023-1 LLC (together, Ashland 2023-1), an aviation loan ABS transaction.

Key Points: 
  • KBRA assigns preliminary ratings to four series of notes issued by APL Finance 2023-1 Designated Activity Company and APL Finance 2023-1 LLC (together, Ashland 2023-1), an aviation loan ABS transaction.
  • Ashland 2023-1 represents the inaugural aviation loan ABS transaction that is sponsored and serviced by Ashland Place Finance LLC (APL or the Company).
  • The Company is owned by Davidson Kempner Capital Management LP (DKCM), and, together with DKCM, is comprised of over 500 individuals operating out of seven offices with headquarters in New York City.
  • Proceeds from the Notes will be used to acquire a portfolio of 11 loan facilities (the Facilities) comprised of 26 loans (the Assets, and together with the Facilities, the Portfolio).

Adani Power to Co-fire Green Ammonia at its Mundra Plant for a Sustainable Future

Retrieved on: 
Wednesday, November 29, 2023
Research, Environment, Climate Change, Utilities, Chemicals, Plastics, Sustainability, Alternative Energy, Manufacturing, Energy, Science, NEDO, Carbon, New energy, CO2, APL, Electrolysis, IHI, Adani Power, Renewable energy, Conference, Ammonia, CEP, COP, Coal, Kowa

As part of the project, the Mundra Plant, which is India’s largest private sector power plant, will co-fire up to 20% green ammonia in the boiler of a conventional coal fired 330MW Unit.

Key Points: 
  • As part of the project, the Mundra Plant, which is India’s largest private sector power plant, will co-fire up to 20% green ammonia in the boiler of a conventional coal fired 330MW Unit.
  • Green ammonia, produced from green hydrogen, which in turn is produced through electrolysis using renewable energy, would be a feedstock for the boilers.
  • Combustion tests at IHI’s facility in Japan have begun with 20% ammonia blend, simulating Mundra Power Station equipment.
  • The Mundra plant is the first location outside of Japan to have been selected for this cutting-edge green initiative.

The UNH InterOperability Lab Launches Single Pair Power over Ethernet and Power over Data Lines Conformance Testing

Retrieved on: 
Thursday, November 16, 2023
Technology, Networks, Data Management, Telecommunications, IEEE, Fatherland Front (Austria), UNH-IOL, Clause, APL, UNH, Power over Ethernet, SPE, Automation, University, Silicon, Power

The University of New Hampshire InterOperability Laboratory (UNH-IOL), an independent provider of broad-based testing and standards conformance services for the networking industry, today announced that Single Pair Power over Ethernet (SPoE) & Power over Data Lines (PoDL) conformance testing are now available.

Key Points: 
  • The University of New Hampshire InterOperability Laboratory (UNH-IOL), an independent provider of broad-based testing and standards conformance services for the networking industry, today announced that Single Pair Power over Ethernet (SPoE) & Power over Data Lines (PoDL) conformance testing are now available.
  • As part of the recently completed 802.3cg project, UNH-IOL SPoE testing includes additional powering classes for 10BASE-T1L ports.
  • "The UNH-IOL is thrilled to provide neutral conformance testing for SPoE and PoDL to silicon vendors and product developers."
  • To learn more about Power over Ethernet testing services offered at the lab, including 4-pair, 2-pair, SPoE, PoDL, and APL, visit the UNH-IOL website .

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Sale, Webcast, ID, Completeness, Incyte, Patient, Research, Chief commercial officer, APL, Bone marrow, RARA, Acute promyelocytic leukemia, Retirement, AML, Growth, Arsenic trioxide, Syro, Pharmaceutical industry, Management, Cryptocurrency, Pfizer, Syros

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.
  • In October 2023, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., effective December 1, 2023.
  • General and administrative expenses were $7.8 million for the third quarter of 2023, as compared to $8.1 million for the third quarter of 2022.
  • ET to discuss these third quarter 2023 financial results and provide a corporate update.

FluidForm Bio Successfully Demonstrates Advancements in Engineered Heart Tissues with FRESH™ 3D Bioprinting

Retrieved on: 
Tuesday, December 12, 2023
Merck & Co., Research, Disease, Tissue, Hypoxia, Biological engineering, APL, Merck, Tissue engineering, Pharmacology, Cell death, Drug development, Medical imaging

WALTHAM, Mass., Dec. 12, 2023 /PRNewswire/ -- FluidForm Bio, a leader in developing life-like human tissue to treat disease, shares recent advancements in building human cardiac tissues using FRESH™ 3D bioprinting.

Key Points: 
  • WALTHAM, Mass., Dec. 12, 2023 /PRNewswire/ -- FluidForm Bio, a leader in developing life-like human tissue to treat disease, shares recent advancements in building human cardiac tissues using FRESH™ 3D bioprinting.
  • FluidForm Bio has demonstrated potential for bridging this gap using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in three-dimensional tissue structure.
  • Furthermore, by leveraging robotic fabrication, tissues are highly viable and reproducible, maintaining functional response across tissues and batches.
  • "This study was conducted by scientists at FluidForm and Merck & Co.," explained FluidForm Bio CEO and Co-founder Mike Graffeo.